Clinical Trial Update: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dinutuximab with sargramostim and combination chemotherapy for newly diagnosed high-risk neuroblastoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• High-risk Neuroblastoma
• Neuroblastoma

Drugs mentioned

• dinutuximab (dinutuximab)
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ganglioneuroblastoma, High Risk Neuroblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-14